Autolus Therapeutics plc Stock News

LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at...

Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, bu...

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – W...

LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at ...

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. “We are looking forward to presenting longer-term data from adult patients with r/r ALL treate...

Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated with improved event-free survival Autolus will host a conference call and webcast to discuss the presented dat...

Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2024 Earnings Conference Call May 17, 2024 8:30 AM ET Company Participants Olivia Manser – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Kelly Shi – Jefferies James Shin – Deutsche Bank Asthika Goonewardene – Truist Matthew Phipps – Blair Gil Blum – Needham & Company Operat...